First NCFB patient dosed in Phase IIa study of RESP-X

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Infex to present RESP-X Phase I data at ERS Congress

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Infex Therapeutics logo

Infex webinar - broader pipeline and growth strategy

On 9th May 2024, Infex Therapeutics held a live webinar, to update on the…


Infex Therapeutics logo

Infex to present webinar on broader pipeline and growth strategy

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Webinar on Infex's Phase II lead respiratory drug, RESP-X

On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…


RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Clinical candidate nominated for COV-X programme

COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…


Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

First subject dosed in Phase I study to evaluate safety and tolerability of…